Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week randomized, placebo-controlled trial of inhaled CSJ117 in adults with COPD
jRCT2031210454Completed
- Sponsor
- Novartis
- Start
- Jan 2022
- Modality
- Fab Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial of ecleralimab in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Novartis. Primary endpoint: Change in Evaluating Respiratory Symptoms (E-RS) score from baseline. Started Jan 2022; status: completed.
02
Drugs
ecleralimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2031210454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210454.